A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Recurrent vulvovaginal candidiasis (RVVC) is one of the most prevalent fungal infections in humans, especially in developing countries; however, it is underestimated and regarded as an easy-to-treat condition. RVVC may be caused by dysbiosis of the microbiome and other host-, pathogen-, and antifungal drug-related factors. Although multiple studies on host-related factors affecting the outcome have been conducted, such studies on Candida-derived factors and their association with RVVC are lacking. Thus, fluconazole-tolerant (FLZT) isolates may cause fluconazole therapeutic failure (FTF), but this concept has not been assessed in the context of Candida-associated vaginitis. Iran is among the countries with the highest burden of RVVC; however, comprehensive studies detailing the clinical and microbiological features of this complication are scarce. Therefore, we conducted a 1-year prospective study with the aim to determine the RVVC burden among women referred to a gynecology hospital in Tehran, the association of the previous exposure to clotrimazole and fluconazole with the emergence of FLZT and fluconazole-resistant (FLZR) Candida isolates, and the relevance of these phenotypes to FTF. The results indicated that about 53% of the patients (43/81) experienced RVVC. Candida albicans and C. glabrata constituted approximately 90% of the yeast isolates (72 patients). Except for one FLZT C. tropicalis isolate, FLZR and FLZT phenotypes were detected exclusively in patients with RVVC; among them, 27.9% (12/43) harbored FLZR strains. C. albicans constituted 81.2% of FLZR (13/16) and 100% of the FLZT (13/13) isolates, respectively, and both phenotypes were likely responsible for FTF, which was also observed among patients with RVVC infected with fluconazole-susceptible isolates. Thus, FTF could be due to host-, drug-, and pathogen-related characteristics. Our study indicates that FLZT and FLZR isolates may arise following the exposure to over-the-counter (OTC) topical azole (clotrimazole) and that both phenotypes can cause FTF. Therefore, the widespread use of OTC azoles can influence fluconazole therapeutic success, highlighting the necessity of controlling the use of weak topical antifungals among Iranian women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors
Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669 · cited 1×
“In addition, immunodeficiency due to genetic aberrations (Jaeger et al., 2016; Tian et al., 2017), local immune overreaction (Rosati et al., 2020), the inefficiency of prescribed antifungal agents, and, to a lesser extent, the development of antifungal resistance contribute to RVVC. Numerous…”
BackgroundDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Global burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639 · cited 1×
“This observation is consistent with previous studies on VVC (Sharifynia et al., 2017; Ghajari et al., 2018), oral candidiasis (Arastehfar et al., 2019a), and candidemia (Arastehfar et al., 2020d; Kord et al., 2020) in Iran, which documented the abundance of C. albicans among Iranian patients,…”
ResultPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Costa-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
Rosati, D., Bruno, M., Jaeger, M., ten Oever, J., & Netea, M. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020144 · Cited by 206
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“Indeed, a new wave of studies has found the clinical importance of azole tolerance in therapeutic failure [22, 23, 31] and future studies are underway to better understand the underlying mechanism, with the hope of identifying novel targets impairing this mechanism to thwart the emergence of resistance.”
BackgroundSelf-citationEsfahani, A., Omran, A. N., Salehi, Z., Shams-Ghahfarokhi, M., Ghane, M., Eybpoosh, S., & Razzaghi-Abyaneh, M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105696 · Cited by 30
Pan, Y., Sun, Y., Chen, L., Cheng, Y., Jin, P., Zhang, W., Zheng, L., Liu, J., Zhou, T., Xu, Z., et al. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100162 · Cited by 26
“Candida albicans is the major aetiological agent, causing at least three quarters of all RVVC cases [4,5].”
BackgroundMeng, Q., Wang, H., Xiao, W., Mai, W., Liu, Y., Xiao, Y., Wang, P., Sui, J., He, X., Yin, F., et al. (2025) · Mycology · doi:10.1080/21501203.2025.2461725 · Cited by 8
“For example, Arastehfar et al. (2021) reported that 78.6% of yeasts causing VVC and recurrent vaginitis in Iran belonged to C. albicans , followed by C. glabrata (11.7%).”
InfluentialSelf-citation
Metadata
- Authors
- Arastehfar, A., Kargar, M. L., Mohammadi, S. R., Roudbary, M., Ghods, N., Haghighi, L., Daneshnia, F., Tavakoli, M., Jafarzadeh, J., Hedayati, M. T., Wang, H., Fang, W., Carvalho, A., Ilkit, M., Perlin, D. S., & Lass-Flörl, C.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-28
- Volume
- 12
- Pages
- 655069-655069
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W3159730028
- Cited by
- 41
- References
- 15
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.